INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 430m ago
House PTR30m ago
SEC 13F29m ago
Robinhood Chain29m ago

Most active filers · 30d

  1. 01Kurtz George0B / 204S204 trades$51.20M
  2. 02SPSaba Capital Management, L.P.68B / 23S · 14 late91 trades$30.01M
  3. 03ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  4. 04AJAllaire Jeremy0B / 50S50 trades$4.26M
  5. 05Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  6. 06SJSheena Jonathan0B / 43S43 trades$3.14M
  7. 07CFCheng Chi Fung0B / 42S42 trades$15.33M
  8. 08SLSpeiser Michael L0B / 35S35 trades$14.00M
  9. 09RARothblatt Martine A0B / 33S33 trades$5.50M
  10. 10RJRubinstein Julie0B / 33S33 trades$5.33M

Form 4 transactions

19,342 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026
Page 377 of 484
← PrevNext →

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 99 insiders$642K
  4. SELL
Jan 14, 2026
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

36
NR
Neale Erin RoseSVP, Chief Legal Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$40K
2,257 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$6,676
18 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$2,235
6 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$10K
27 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$467K
5,182 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$25K
72 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$467K
5,181 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
SM
Snow Colton MatthewSVP, Chief Commercial Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$13K
759 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$387K
4,240 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
36 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$28K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$1,117
3 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
34 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$32K
87 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

SYMSymbotic Inc.Oct 26 – Nov 2
7 insiders$1.98M
  • BUYUPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
  • SELLADUSAddus HomeCare CorpNov 6 – Nov 96 insiders$16.28M
  • SELLARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
  • BUYBBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K